Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. BioNTech acquires T cell therapy-focused Neon for $67m
  2. MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
  3. AZ to take $100m hit from ending trial of CV drug Epanova
  4. Pfizer signs oncology agreement with STR-focused eFFECTOR
  5. No more siloes: linking rheumatology and CVD with Abcentra

Latest Content

BioNTech acquires T cell therapy-focused Neon for $67m

BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.

Bioequivalence Studies Conduct CRO

For more than two decades, CEPHA has built its reputation for conducting high-quality, cost-effective clinical research services. The company takes pride in maintaining high-quality standards and providing robust, reliable, and time-effective results in contract research.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top